查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198656

移植诊断市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Transplant Diagnostics Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 111 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

移植诊断市场预计在预测期内（2022 年至 2027 年）的复合年增长率为 7.8%。

COVID-19 对所调查市场的增长产生了重大影响。 根据一项题为“实体器官移植中 COVID-19 的诊断测试”的研究。 在 2020 年 10 月的“当前临床应用和未来策略”中，实体器官移植的多个方面受到 COVID-19 流行病的影响，包括供体和受体的适用性、移植后感染和感染预防。我在这里。 在 COVID-19 大流行期间，对 SARS-CoV-2 在免疫功能低下患者中的诊断保真度和传染性的了解不断增加，继续指导实体器官移植的最佳实践。 因此，由于在大流行期间与移植相关的挑战，COVID-19 对市场增长产生了显着影响。

移植是许多长期接受透析的终末期肾病患者的首选治疗方法之一。 在涉及心臟、肝臟和骨髓的病例中，移植也是一种可行的选择。 此外，随着公司投资开发更好的 HLA 分型技术、抗体监测、仪器和软件，诊断技术在过去十年中有了显着改善。 在体内移植各种器官时，它越来越多地用于诊断目的。

器官捐献的增加极大地促进了被调查市场的增长。 根据器官获取组织协会（AOPO）2021 年 1 月发布的数据，2020 年有超过 12,500 人捐献了一个或多个器官，比上一年增长了 6%。 2020年死者器官捐献超过3.65万件，同比增长近2%。 它还报告说，在过去七年中，死者器官挽救了 33,000 多条生命，超过了前一年的总数。 心血管死后捐赠 (DCD) 捐款也显着增加，2020 年捐赠者超过 3,000 人。 器官捐赠的增加导致对移植诊断测试的需求增加，从而推动了市场的增长。

此外，市场参与者推出新产品也有助于市场的增长。 例如，2021 年 9 月，Thermo Fisher Scientific 在美国组织相容性和免疫遗传学 (ASHI) 年会上为其移植诊断产品组合增加了两种新产品。

然而，高移植成本、不规范的保险和报销政策以及与器官移植相关的社会和伦理问题可能会阻碍预测期内的市场增长。

移植诊断试剂市场趋势

在预测期内，实体器官移植板块有望占据主要份额

在预测期内，实体器官移植领域预计将占据主要份额。 实体器官移植始于 20 世纪的一种实验方法，现在被认为是终末期器官功能障碍患者的既定且可行的治疗选择。 大多数移植是针对肾臟进行的，其次是肝臟。

根据卫生资源服务局 2022 年 2 月的数据，美国有超过 106,000 人在实体器官移植的国家移植等待名单上。 等待实体器官移植的人群比例为肾臟（83%）、肝臟（11%）、胰腺（1%）、心臟（3%）和其他（2%）。 预计对实体器官的需求增加将需要增加移植测试，从而在预测期内推动该行业的增长。

此外，器官移植检测的增加预计将推动这些检测的采用，从而推动该细分市场的增长。 例如，2021 年 9 月，通过基因检测和无细胞 DNA (cfDNA) 检测转变护理的领先公司之一 Natera Inc. 将推出 Prospera with Quantification，这是一种用于肾臟排斥反应的 cfDNA 检测。

此外，增加对实体器官移植的资助将进一步促进预测期内所研究市场的增长。 例如，根据美国国立卫生研究院（NIH）2022年5月的数据，2020年和2021年用于器官移植研究的经费分别为2.08亿美元和2.01亿美元。 由于在研究中越来越多地采用移植诊断，预计对实体器官移植研究的如此高额资助将进一步推动这一领域的增长。

因此，上述因素预计将在预测期内推动该细分市场的增长。

预计在预测期内北美将占据所研究市场的主要份额

北美占移植诊断市场的主要份额，预计在预测期内将保持相同的增长速度。

该地区的国家（例如美国和加拿大）拥有完善的资助机构、基础设施以及政府参与筹集资金和提高意识以促进患者器官移植的能力。 例如，根据美国国立卫生研究院2022年5月的数据，2020年、2021年和2022年（预计）用于移植的研究经费将分别达到7.21亿美元、7.02亿美元和7.35亿美元。 因此，增加对移植研究的资助将导致移植诊断的使用增加，从而推动该地区的市场增长。

此外，根据2022年2月公布的《器官捐献统计》，2021年美国进行了4万多例器官移植。 因此，在预测期内，增加移植将推动该市场的增长。

预计主要市场参与者不断增加的举措将有助于市场的进一步增长。 这些公司在用于快速诊断移植前后疾病的新产品的营销方面取得了进展，并被美国和加拿大的私人和政府机构广泛接受。 例如，2022 年 3 月，致力于加快评估早期肾臟损伤的生物技术公司 Nephrosant 宣布招募了第一位患者。 将招募多达 2,000 人并观察 24 个月。 在此期间，QSant 测试和标准诊断程序用于寻找急性排斥反应的证据。 预计这种类型的测试将进一步推动北美移植诊断试剂市场的增长，北美的移植诊断测试正变得越来越普遍。

因此，由于上述因素，北美地区有望在预测期内实现增长。

移植诊断市场竞争者分析

移植诊断市场的竞争是温和的。 在试剂功效、可负担性、改善临床医生决策和意识以及充足的器官储存设施方面的技术进步是公司在预测期内必须克服的一些当前机遇和挑战。它被认为是。 移植诊断市场的主要参与者包括 Abbott Laboratories、Biomerieux SA、F Hoffmann La Roche AG、Qiagen NV、Thermo Fisher Scientific Inc. 等公司。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动力
    • 移植手术增加
    • 移植诊断试剂的技术进展
    • 政府与私营部门合作，为目标疾病的研究提供资金
  • 市场製约因素
    • 移植成本高
    • 保险和报销政策
    • 与器官移植相关的社会和伦理问题
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按技术
    • 分子
      • 基于 PCR 的分子检测
      • 基于测序的分子检测
    • 非分子
  • 按产品分类
    • 设备
    • 试剂
    • 软件
  • 按移植类型
    • 实体器官
    • 干细胞
    • 软组织
  • 通过申请
    • 诊断
    • 调查
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 法国
      • 德国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Biomerieux SA
    • Bio-Rad Laboratories Inc.
    • CareDx
    • F Hoffman-La Roche AG
    • Hologic Inc.
    • Illumina Inc.
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
    • Immucor, Inc.
    • Omixon Ltd.
    • GenDx
    • BioGenuix

第7章 市场机会与今后动向

简介目录
Product Code: 67617

The transplant diagnostics market is poised to register a CAGR of 7.8% during the forecast period (2022-2027).

COVID-19 had a significant impact on the growth of the studied market. According to the study titled "Diagnostic Testing of COVID-19 in Solid Organ Transplantation: Current Clinical Application and Future Strategies" in October 2020, multiple elements of solid organ transplantation have been impacted by the COVID-19 pandemic, including donor and recipient appropriateness, as well as infection and transmission prevention following transplantation. During the COVID-19 pandemic, growing knowledge about the diagnostic fidelity and transmissibility of SARS-CoV-2 in immunocompromised patients continued to guide best practices for solid organ transplantation. Thus, owing to the challenges associated with transplantation amid the pandemic, COVID-19 had a pronounced impact on the growth of the market.

Transplantation is one of the preferred treatment options for many patients suffering from end-stage renal disease and undergoing chronic dialysis therapy. Also, transplantation is a viable option considered in cases associated with the heart, liver, and bone marrow. Additionally, in the past decade, diagnostics have improved significantly as companies have been committed to develop better HLA typing technologies, antibody monitoring, instruments, and software. This is gradually being used for diagnostics during the transplantation of different organs of the body.

The rising donation of organs is one of the major contributors to the growth of the studied market. According to the data published by the Association of Organ Procurement Organizations (AOPO) in January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the previous year. The number of organs donated from dead donors increased to over 36,500 in 2020, which is almost a 2% increase year over year. It also reported that in the past seven years, organs from the dead have saved more than 33,000 lives, exceeding the previous year's totals. There were also notable increases in donations after circulatory death (DCD) contributions, which totaled more than 3,000 donors in 2020. The rise in organ donation creates the need for increased transplant diagnostic testing and thus drives the growth of the market.

Moreover, the launch of new products by the market players also contributes to the growth of the market. For instance, in September 2021, Thermo Fisher Scientific added two new products to its transplant diagnostics portfolio during the American Society for Histocompatibility and Immunogenetics (ASHI) annual conference.

However, the high cost of transplants, irregular insurance and reimbursement policies, and social and ethical issues related to organ transplants may hinder the growth of the market over the forecast period.

Transplant Diagnostics Market Trends

Solid Organ Transplant Segment is Expected to Hold a Major Share over the Forecast Period

The solid organ transplant segment is expected to hold a major share over the forecast period. Solid-organ transplantation was started as an experimental approach in the 20th century and is now considered a well-established and practical treatment option for patients suffering from end-stage organ dysfunction. The majority of transplants are done for kidneys, followed by the liver.

According to the Health Resources and Services Administration in February 2022, there are over 106,000 people on the national transplant waiting list for solid organ transplantation in the United States. The percentage of people waiting for solid organ transplants includes the kidney (83%), liver (11%), pancreas (1%), heart (3%), and others (2%). The rise in demand for solid organs creates a need for increased testing for transplantation, which is expected to drive the growth of the segment over the forecast period.

In addition, the rising number of organ transplant tests will also drive the growth of this segment due to the rise in the adoption of these tests. For instance, in September 2021, Natera Inc., one of the key players in transforming care through genetic and cell-free DNA (cfDNA) testing, launched Prospera with Quantification, the cfDNA test for kidney rejection.

Moreover, rising funding for solid organ transplantation will further contribute to the growth of the market studied over the forecast period. For instance, according to the National Institutes of Health (NIH) in May 2022, the funding for organ transplant research in 2020 and 2021 was USD 208 million and USD 201 million, respectively. Such high funding for solid organ transplant research will drive the growth of this segment further due to the rise in the adoption of transplant diagnostics in research.

Therefore, owing to the above-mentioned factors, this segment's growth is expected to drive over the forecast period.

North America is Expected to Hold a Major Share in the Studied Market Over the Forecast Period

North America is expected to hold a major share in the transplant diagnostics market and is expected to continue at the same pace over the forecast period.

Countries of the region such as the United States and Canada are well-equipped with the funded organizations, infrastructure, and government participation in raising funds and awareness to promote the transplantation of organs for patients. For instance, according to the National Institute of Health in May 2022, the funding for research in transplantation was USD 721 million, USD 702 million, and USD 735 million in 2020, 2021, and 2022 (estimated) respectively. The rise in funding for transplantation research will therefore lead to increased utilization of transplant diagnostics and drive the growth of the market in this region.

In addition, according to the Organ Donation Statistics published in February 2022, more than 40,000 organ transplantations took place in the United States in 2021. The rise in transplantations will therefore drive the growth of this market over the forecast period.

Rising initiatives from the key market players are expected to contribute to the market's growth further. These companies are advanced in marketing new products for faster diagnostics of diseases before and after the transplants, which are well accepted by the private organizations and governments of the United States and Canada. For instance, in March 2022, NephroSant, a biotechnology firm devoted to speeding up the assessment of early kidney damage, recruited the first patient in the Evaluation of QSant for Underlying Allograft Rejection (AQUA) study. Up to 2,000 people will be enrolled and observed for 24 months, during which time QSant testing and standard-of-care diagnostics will be used to look for evidence of acute rejection. This type of trial will further boost the market growth of transplant diagnostics in North America due to the greater adoption of transplant diagnostic tests.

Thus, owing to the abovementioned factors, the North American region is expected to project growth over the forecast period.

Transplant Diagnostics Market Competitor Analysis

The market for transplant diagnostics is moderately competitive. The technological advancements, in terms of reagent effectiveness, affordability, clinicians' decision-making and raising awareness, and proper organ preservation facilities, are some of the present-day opportunities and challenges that the companies are expected to overcome during the forecast period. Some of the major companies expanding in the transplant diagnostics market include Abbott Laboratories, Biomerieux SA, F Hoffmann La Roche AG, Qiagen NV, and Thermo Fisher Scientific Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Transplant Procedures
    • 4.2.2 Technological Advacements in Transplant Diagnostics
    • 4.2.3 Government and Private Collaboration into Funding Research of Target Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Transplant
    • 4.3.2 Insurance and Reimbursement Policies
    • 4.3.3 Social and Ethical Issues Related to Organ Transplant
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Technology
    • 5.1.1 Molecular
      • 5.1.1.1 PCR-based Molecular Assays
      • 5.1.1.2 Sequencing-based Molecular Assays
    • 5.1.2 Non-molecular
  • 5.2 By Product
    • 5.2.1 Instrument
    • 5.2.2 Reagent
    • 5.2.3 Software
  • 5.3 By Transplant Type
    • 5.3.1 Solid Organ
    • 5.3.2 Stem Cell
    • 5.3.3 Soft Tissue
  • 5.4 By Application
    • 5.4.1 Diagnostic
    • 5.4.2 Research
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 France
      • 5.5.2.2 Germany
      • 5.5.2.3 United Kingdom
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Biomerieux SA
    • 6.1.4 Bio-Rad Laboratories Inc.
    • 6.1.5 CareDx
    • 6.1.6 F Hoffman-La Roche AG
    • 6.1.7 Hologic Inc.
    • 6.1.8 Illumina Inc.
    • 6.1.9 Qiagen NV
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Immucor, Inc.
    • 6.1.12 Omixon Ltd.
    • 6.1.13 GenDx
    • 6.1.14 BioGenuix

7 MARKET OPPORTUNITIES AND FUTURE TRENDS